Evaluation of the effectiveness of Devivit Carnitine in the treatment of lactating cows with myocardosis

The article presents the results of a study evaluating the effectiveness of pathogenetic therapy in lactating cows with myocardosis using the drugs Devivit Carnitine and Carnivet-L. Devivit Carnitine is a complex remedy containing carnitine hydrochloride, vitamins E and B₁₂, methionine, selenium, and zinc. The application of pathogenetic therapy with Devivit Carnitine and Carnivet-L contributed to improving the clinical condition of lactating cows suffering from myocardosis. By the 7th day of treatment, pain in the heart area was reduced, the force of the heartbeat normalized, and the mucous membranes regained a pale pink color. Clinical recovery was observed in 80.0 % of the animals in the first experimental group (Devivit Carnitine) and in 70.0 % of the animals in the second group (Carnivet-L) after completing a 21-day course of treatment. Despite the positive dynamics, persistent disorders of myocardial conductivity remained in some cows (20.0 % and 30.0 %, respectively). Clinical and biochemical blood parameters (erythrocyte count, hemoglobin concentration, total protein and albumin levels) in the experimental groups began to normalize by day 14 of treatment, with full stabilization achieved by day 28. Administration of Devivit Carnitine led to a more significant increase in erythrocytes, hemoglobin, total protein, and albumins (by 12.5; 19.7; 13.9; and 22.2 %, respectively; P < 0.05), and a more effective reduction in leukocytes, urea, LDH, ALT, and AST (by 20.4; 29.9; 30.9; 33.9; and 55.1 %, respectively; P < 0.05), indicating higher biochemical efficacy compared to Carnivet-L. The results support the feasibility of using Devivit Carnitine as an effective agent in the pathogenetic therapy of myocardosis in lactating cows, due to its positive impact on clinical condition and normalization of key biochemical blood parameters.